MREO | Mereo BioPharma Group plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.52 - 3.62
52 Week Range	1.9500 - 5.02
Beta	0.29
Implied Volatility	108.46%
IV Rank	44.73%
Day's Volume	273,698
Average Volume	754,966
Shares Outstanding	154,734,459
Market Cap	549,307,329
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-04-24

Valuation
Profitability
Growth
Health
P/E Ratio	-11.83
Forward P/E Ratio	N/A
EPS	-0.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	33
Country	UK
Website	MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

MREO's peers: ABEO, ABOS, ADAP, ADVM, AFMD, AGEN, AGIO, AMLX, APLS, ARDX, ATRA, BCLI, BCTX, BHVN, BIVI, BLRX, BMRN, BPMC, BTAI, CMRX, CPRX, CRBP, CRDF, CRIS, CRVS, CTXR, DAWN, DTIL, ELDN, ETNB, EXAI, EYPT, FGEN, FOLD, GLMD, GNPX, HOOK, HRTX, INZY, KPTI, KZIA, LPTX, LXRX, MDGL, TERN, PDSB, XFOR, EFTR, ELEV, HEPA, NCNA, NERV, OCUL, ORMP, PIRS, PYXS, RIGL, SLRX, SLS, VCEL, VIRX, VKTX, VRNA, VYGR, WVE, XERS, GPCR

*Chart delayed

Analyzing fundamentals for MREO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see MREO Fundamentals page.

Watching at MREO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MREO Technicals page.